Kasturi Pharmaceuticals IPO Issue to Raise Rs 16 Crore
15th March 2026, Kathmandu
Kasturi Pharmaceuticals Limited has officially announced its Initial Public Offering (IPO), aiming to raise 160 million rupees through the issuance of 1.6 million ordinary shares.
Kasturi Pharmaceuticals IPO Issue
This public offering represents a strategic capital infusion for a company with over 13 years of operational history in Nepal’s pharmaceutical sector. By offering these shares at a face value of 100 rupees, the company intends to finalize its expansion phase, which will see its total paid-up capital reach 800 million rupees.
Capital Structure and Financial Foundation
The IPO is part of a broader capital management plan that includes founder contributions. The total paid-up capital of 800 million rupees will be comprised of existing founder investments and the new capital raised through this 160 million rupee public offering.
The company has taken significant steps to clean its balance sheet prior to this public market entry. According to official disclosures, Kasturi Pharmaceuticals has aggressively reduced its debt burden, leaving only 240 million rupees in outstanding loans. This improved debt-to-equity profile is a positive signal for potential investors. Furthermore, with a reported net worth per share of 129.93 rupees—well above the 100 rupee issue price—the stock is being introduced at a price point that suggests solid asset backing.
Credit Rating and Risk Assessment
Infomerics Credit Rating Nepal has assigned a BB- (Double B Minus) issuer rating to the company. In the context of the Nepali capital market, this rating reflects a balance between the company’s established operational scale and the inherent risks of the manufacturing industry. It indicates that while the company possesses moderate financial stability, it remains sensitive to market fluctuations, regulatory changes in the drug pricing sector, and competitive pressure from both domestic and imported pharmaceutical products.
Operational Capacity and Leadership
With over 182 approved pharmaceutical formulations and 125 products currently in circulation across the Nepali market, Kasturi Pharmaceuticals has established a mature footprint in the healthcare supply chain. The company operates from a substantial manufacturing site spanning 1 bigha and 10 kattha, which provides the necessary industrial infrastructure for future scale-up.
Leadership continuity is another focal point for investors. The company is steered by:
Advertisement
Executive Chairman Prabek Khanal
Managing Director Ishwor Bhandari
Both executives bring over 30 years of industry-specific experience, which the company emphasizes as a pillar of its strategic resilience and ability to navigate Nepal’s complex drug distribution network.
The Role of Reliable Capital
Reliable Capital Investment and Merchant Limited has been appointed as the issue and sales manager. Their role is critical in ensuring that the IPO adheres to the strict regulatory standards set by the Securities Board of Nepal (SEBON). As the merchant banker, they will oversee the verification of applications, coordinate with the C-ASBA system to ensure efficient allotment, and manage the transparency of the share distribution process.
Sector Outlook: Investing in Domestic Healthcare
The domestic pharmaceutical sector in Nepal is currently a high-growth area, driven by an aging population, increased medical coverage, and a national mandate to reduce reliance on imported medicines. By investing in a local manufacturer like Kasturi Pharmaceuticals, shareholders are participating in a sector that is increasingly vital to national security and public health.
As the IPO launch date approaches, prospective investors are advised to keep a close watch on the official prospectus, which will provide deeper insights into the company’s quarterly performance and profit projections. The transition to a publicly traded company will likely subject Kasturi Pharmaceuticals to higher levels of financial scrutiny, which is generally a positive development for long-term governance and operational transparency.
For More: Kasturi Pharmaceuticals IPO Issue
